Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | AR | P10275 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.33 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3597375 | 0.78 | RAB9A (0.41) | MAPTRAB9ANPC1ARKDM4E | |
| SCHEMBL12004479 | 0.78 | HCAR2 (0.33) | LOXL2 | |
| SCHEMBL990825 | 0.78 | CYP2A6 (0.39) | CYP1A2CYP3A4 | |
| SCHEMBL990826 | 0.77 | — | — | |
| SCHEMBL501228 | 0.75 | CYP2A6 (0.39) | NPC1ARCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL989535 | 0.75 | CYP2A6 (0.52) | LMNAMAPTRAB9ANPC1CYP1A2 | |
| SCHEMBL9594088 | 0.74 | HSP90AA1 (0.37) | MAPTCYP3A4CYP2D6GSK3B | |
| SCHEMBL6460701 | 0.71 | NISCH (0.53) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL8632924 | 0.71 | MAOA (0.35) | MAPTCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL17626014 | 0.70 | KMO (0.49) | LMNAMAPTRAB9ANPC1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008296-B2 | Histamine H3 receptor agents, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2011-08-30 | — | — | US | claimed |
| EP-2322506-A1 | Histamine H3 receptor agents, preparation and therapeutic uses | Eli Lilly and Company (US) | 2011-05-18 | — | — | EP | claimed |
| US-20100160319-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | BEAVERS LISA SELSAM | 2010-06-24 | — | — | US | claimed |
| US-7666871-B2 | 3-Methyl-6-(4-{5-methyl-4-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-oxazol-2-yl}-phenyl)-pyridazine; for treatment of obesity, cognitive deficiencies, narcolepsy | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | claimed |
| CN-100513386-C | Amides for inhibiting interleukin 8-induced chemotaxis of neutrophils | DOMP S P A (IT) | 2009-07-15 | — | — | CN | claimed |
| EP-1786790-B1 | OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2009-06-03 | — | — | EP | claimed |
| EP-1928844-A2 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2008-06-11 | — | — | EP | claimed |
| EP-1904442-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2008-04-02 | — | — | EP | claimed |
| US-20070197604-A1 | Oxazole derivatives as histamine h3 receptor agents,preparation and therapeutic uses | ELI LILLY AND COMPANY | 2007-08-23 | — | — | US | claimed |
| EP-1786790-A1 | OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-05-23 | — | — | EP | claimed |
| US-20070072862-A1 | Bis-aryl amide compounds and methods of use | AMGEN INC. | 2007-03-29 | — | — | US | claimed |
| WO-2007022380-A2 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2007-02-22 | — | — | WO | claimed |
| WO-2007005503-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-01-11 | — | — | WO | claimed |
| WO-2006019833-A1 | OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-02-23 | — | — | WO | claimed |
| WO-2004022567-A1 | HETEROARYL-ETHANOLAMINE DERIVATIVES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-18 | — | — | WO | claimed |
| EP-3068758-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | The Wistar Institute Of Anatomy And Biology (US) | 2016-09-21 | — | — | EP | disclosed |
| WO-2015073864-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | THE WISAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2015-05-21 | — | — | WO | disclosed |
| US-20020151724-A1 | Serine protease inhibitors | ELI LILLY AND COMPANY | 2002-10-17 | — | — | US | disclosed |
| WO-2001096304-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| CN-1182425-A | Benzimidazole compounds and their use as modulators of the GABAA receptor complex | NEUROSEARCH AS (DK) | 1998-05-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197604-A1 | Oxazole derivatives as histamine h3 receptor agents,preparation and therapeutic uses | HCRTR1, HRH3, HCRTR2 | LMNA 4551/4885MAPT 1649/4885RAB9A 1983/4885 |
| US-20070072862-A1 | Bis-aryl amide compounds and methods of use | LCK, BTK, IRAK1 | LMNA 2103/4885MAPT 4311/4885RAB9A 2344/4885 |
| US-20100160319-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | HRH3, HRH4, HCRTR1 | LMNA 4368/4885MAPT 825/4885RAB9A 1469/4885 |
| US-20020151724-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | LMNA 70/4885MAPT 4835/4885RAB9A 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.